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Abstract (word count: 250) 
Background: Tumour stage was introduced to the Swedish Cancer Registry 
in 2004, but this key variable for prognostic research has not yet been 
validated. We validated the tumour stage data in surgically treated 
oesophageal cancer patients.  
Material and Methods: Completeness and accuracy of tumour stage 
according to the TNM system (“Tumour Node Metastasis”) in the Cancer 
Registry were compared with a cohort study including comprehensive 
tumour stage data based on the pathological TNM of almost all patients 
operated for oesophageal cancer in 2006-2010 in Sweden.  
Results: Of the 397 patients with pathological TNM data in the comparison 
cohort, the Cancer Registry reported an overall TNM stage in 390 patients 
(98.2%), which was based on the pathological TNM of 104 patients (26.2%), 
the clinical TNM of 183 patients (46.1%), and the pathological or clinical 
TNM (undefined) of 110 patients (27.7%). The completeness for the 
separate T, N, and M components was 89.4%, 90.9%, and 85.1%, 
respectively. The concordance with tumour stage was 98.2%, while it was 
51.1%, 70.5%, and 80.4% for the separate T, N, and M components, 
respectively. While the concordance with tumour stage was high for all TNM 
assessment groups (98.1-98.4%), the concordance of the T and N 
components was highest when using pathological TNM (82.7% and 95.2%, 
respectively), and the concordance of the M component was highest when 
using clinical TNM (88.5%).  
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Conclusion: Although the overall completeness of tumour stage is high, the 
recording of pathological TNM stage and individual components could be 
improved within the Swedish Cancer Registry.  
 





Tumour stage is the most important prognostic factor for oesophageal 
cancer, a cancer characterised by a 5-year overall and postoperative 
survival of less than 15% and 35%, respectively.1 Accurate cancer staging is 
crucial for predicting prognosis and deciding on treatment for these patients, 
and prognostic research heavily relies on accurate tumour stage data. The 
most commonly used staging system for oesophageal cancer is based on 
the TNM classification, which includes the local tumour growth (T), lymph 
node involvement (N) and distant metastases (M). TNM staging has been 
used since 1946 and has been updated regularly since, both by the Union 
International Contre le Cancer (UICC) and the American Joint Committee on 
Cancer (AJCC).2, 3 TNM of oesophageal cancer is usually specified as 
clinical (cTNM) when it is based on findings from endoscopy and imaging 
prior to clinical decision-making, or pathological (pTNM) if it is based on a 
histological examination of a surgically resected specimen. Since pTNM is 
based on clinical information, supplemented or modified by the additional 
evidence acquired from surgery and from pathological examination, it is 
considered the most accurate way to report TNM.4 Information from the 
Swedish Cancer Registry is often used in cancer research, including 
prognostic studies, which highlights the need for complete and correct TNM 
registration. Tumour stage was added as a variable to the Swedish Cancer 
Registry in 2004, and this variable has, to the best of our knowledge, not 
been scientifically validated. Therefore, the objective of this study was to 
validate the completeness and accuracy of the TNM data available in the 
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Swedish Cancer Registry in comparison with pTNM data collected in a 
comprehensive, nationwide Swedish cohort of oesophageal cancer patients 
who underwent tumour resection.  
 
Material and Methods 
Design  
This was a validation study evaluating the completeness and accuracy of the 
TNM data, including the overall tumour stage, and T, N and M components, 
in the Swedish Cancer Register among patients who underwent surgical 
resection for oesophageal cancer during the period 1st January 2006 to 31st 
December 2010. The comparison group (“gold standard”) was a well-
established nationwide Swedish cohort of oesophageal cancer patients, 
including high-quality data on pTNM, which has previously been used to 
investigate causes, surgical treatment and outcome in oesophageal cancer.5, 
6
 The study was approved by the Regional Ethical Review Board in 
Stockholm, Sweden.  
    
Swedish Cancer Registry 
The Swedish Cancer Registry was founded in 1958 and has since captured 
the whole Swedish population. Registration by clinicians and pathologists is 
compulsory for all new cancer cases diagnosed clinically, morphologically or 
by laboratory tests or autopsy. Information about the patients as well as the 
type, site, histology and date of the cancer diagnosis is recorded. The overall 
completeness of cancer diagnoses in general is very high,7 and it is 98.3% 
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complete for oesophageal cancer.8 TNM-staging was introduced in 2004, but 
we decided to start this validation study in 2006, since incomplete and 
suboptimal reporting of TNM in the Cancer Registry was expected during the 
initial period. The 6th edition of the TNM classification of the UICC was used 
to define TNM in the Cancer Registry (and in the comparison cohort).4 The 
doctors were required to fill in the information of every patient diagnosed 
with cancer, including text boxes for T, N and M, as well as tick boxes for 
whether the basis of the evaluation was clinical (cTNM) or pathological 
(pTNM). Whenever possible, reporting of pTNM was preferred over cTNM in 
the Cancer Registry, yet only one of both could be reported. The timing of 
the TNM staging was not collected in the Cancer Registry. The overall 
tumour stage was based on the summary of the reported T, N and M 
components and reproduced by the Cancer Registry. The board of health 
and welfare (Socialstyrelsen) recommends that these data should be 
reported as soon as the diagnosis is established and the required 
information is available, by the physician responsible for the clinical 
diagnosis of newly discovered tumours or tumour-like conditions. These data 
should then be sent to one of the six regional cancer centres in Sweden, 
where they are coded and registered, and then send to the National Board of 
Health Register and Welfare to be implemented in the Cancer Registry.   
 
Comparison cohort 
Our population-based surgery cohort study that was used as the comparison 
(“gold standard”) included 97% of all patients who underwent curatively 
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intended surgery for oesophageal cancer in Sweden during 1st January 1987 
to 31st December 2010. Since the dataset of this comparison cohort included 
data from the year 2010, this was the final year of the present study. The 
comparison cohort is described in more detail elsewhere.5, 9 In brief, its 
members were identified by linking data from the Swedish Cancer Registry 
and Swedish Patient Registry. The personal identity numbers, a 10-digit 
unique personal identifier of each person residing in Sweden, enabled 
registry linkages and retrieval of surgery and histopathology records from all 
hospitals involved in patients with oesophageal cancer in Sweden. All 
departments of pathology in Sweden were asked to send a copy of the 
histopathological record to the study secretariat for every patient in the study 
cohort. 5 Tumour stage, location, and histological type were manually 
reviewed by one investigator and two investigators checked a random 
sample of this classification and found it to be highly accurate.5 Only patients 
with complete pTNM staging information were included in the comparison 
cohort. pTNM information was based on the histology reports and medical 
charts and defined by the 6th edition of the TNM classification of the UICC.4 
Data were collected on the overall tumour stage as well as the separate T, N 
and M components.  
 
Statistical analysis  
Patients were classified into three TNM groups depending on whether the 
basis of the TNM was pathological (pTNM), clinical (cTNM), or unspecified 
(pTNM or cTNM). Patient-, tumour-, and treatment characteristics were 
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compared, i.e. sex (male or female), age at diagnosis (three equally sized 
groups), tumour histology (adenocarcinoma or squamous cell carcinoma), 
calendar year of surgery (per year), hospital volume of oesophagectomies 
(three equally sized groups) and hospital type (university or non-university). 
For each group, the TNM classification as reported in the Cancer Registry 
was assessed for completeness and accuracy of the overall stage and each 
T, N and M component. Stage was categorised into 4 groups (0-I, II, III, or 
IV), the T component into four groups (T0-1, T2, T3 or T4), the N component 
into two groups (N0 or N1), and the M component into two groups (M0 or 
M1), all according to the 6th edition of the TNM classification of the UICC.4 
The categorisation of overall tumour stage used for our analyses is 
presented in Figure 1. Accuracy was expressed as concordance or the 
proportion of all scores that were identical in both data sources. The Cohen’s 
Kappa statistic was used to evaluate the concordance between variables 
from the two cohorts, with a Kappa of 1 indicating complete concordance.10 
All analyses were performed using the statistical software STATA (Stata 




Among 410 patients who underwent oesophagectomy for oesophageal 
cancer between 2006 and 2010 in Sweden, 13 were excluded because of 





Basis of the tumour stage assessment in the Cancer Registry 
Although the records of all study patients indicated that the cancer diagnosis 
in the Cancer Registry was based on “biopsy or operation with 
histopathological investigation”, pTNM was reported for only 104 patients 
(26.2%), while cTNM was reported for 183 patients (46.1%). For the 
remaining 110 patients (27.7%) it was not specified if any TNM information 
was based on clinical or pathological examination (Figure 2). As seen in 
Table 1, pTNM was reported more frequently in men, non-university 
hospitals and low-volume hospitals compared to their counterparts. The 
basis of tumour stage data was not specified in 84.6% of the patients in 
2006, after which this proportion declined substantially. During the years 
2008-2010, cTNM was reported approximately twice as frequently as pTNM. 
Patient age did not appear to influence the reported basis of tumour stage 
(Table 1). 
 
Completeness of tumour stage and T, N, and M components in the 
Cancer Registry 
For 395 out of 397 patients (99.5%) at least some information was reported 
on tumour stage or one or more of the T, N or M components in the Cancer 
Registry. The overall completeness of tumour stage and the T, N, and M 
components in the Cancer Registry was 98.2%, 89.4%, 90.9%, and 85.1%, 
respectively. The completeness is presented in Table 2 for all three TNM 
groups (pTNM, cTNM, and unspecified basis for TNM). The completeness of 
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tumour stage was similar in all three types of TNM assessments (range 
98.1-98.4%)(Table 2). Most cases where T, N and M components were 
missing were patients in whom TNM was not specified. The completeness 
was higher for the pTNM data than the cTNM data for the T component 
(97.1% and 92.3%, respectively) and the N component (99.0% and 95.6%, 
respectively), while the M component was less complete in the pTNM group 
compared to the cTNM group (85.6% and 95.1%, respectively).  
 
Accuracy of tumour stage and T, N, and M components in the Cancer 
Registry 
The overall reporting concordance and Kappa statistics are presented in 
Table 2. The overall concordance between the Cancer Registry and the 
comparison cohort for tumour stage and T, N, and M components was 
98.2% (kappa 0.97), 51.1% (kappa 0.34), 70.5% (kappa 0.46), and 80.4% 
(kappa 0.12), respectively. For all three types of TNM assessments, there 
was high concordance for stage (range 98.1-98.4%, kappa 0.97-0.98), 
meaning that if tumour stage was reported, it was virtually identical to the 
tumour stage reported in the comparison cohort. The concordance for the T 
and N components was highest in the pTNM group, with 82.7% (kappa 0.76) 
for the T component and 95.2% (kappa 0.90) for the N component, while the 
concordance for the M component was highest in the cTNM group (88.5%; 





This validation study of tumour stage recorded in the Swedish Cancer 
Registry among patients operated for oesophageal cancer found a low 
reporting of pTNM, but when adding cTNM and unspecified basis for TNM 
the overall tumour stage was almost complete and highly accurate. The 
reporting of the separate TNM components was suboptimal, especially for 
the T and N components when the pTNM was not available.  
 
A main strength of this study is the virtually complete assessment of eligible 
patients, which counteracts selection bias. Other advantages include the 
restriction to patients who underwent surgery, and therefore pathological 
examinations of the resected specimens were performed, as well as the 
accurate data of pathological tumour stage in the comparison cohort. A 
limitation is the lack of tumour stage data after the year 2010. A newer 
version (7th) of the TNM classification has been introduced, 11 but the 6th 
edition is currently still in use for reporting the TNM in the Swedish Cancer 
Registry.11 Another limitation is that we grouped some of the variables to 
obtain sufficiently large categories, including grouping of the tumour stage 
and T component into 4 groups rather than more specific categories. Finally, 
we did not have data on cTNM in the comparison cohort, which means that 
we could not validate this variable in any detail.  
 
Although other validation studies have been performed to assess the quality 
of the Swedish Cancer Registry,12, 13 this is to the best of our knowledge, the 
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first validation study of the TNM staging in specific . It is unclear why pTNM 
is underreported, although it is requested from the Cancer Registry, and we 
cannot assess if differences in quality of TNM registration exist between the 
six regional cancer centres, or different hospitals. Possible explanations for 
the incomplete reporting of both pTNM and cTNM and the suboptimal 
reporting of the T, N, and M components in the Cancer Registry are that it is 
unclear who among the clinicians within the multidisciplinary team 
(oncologist, surgeon or pathologist) should report this data to the Cancer 
Registry, leaving a risk of non-reporting or that the quality of the reporting is 
decreased. It is also unclear what could happen if two different clinicians 
send it this registration form for the same patient and same cancer episode, 
when it contains slightly different information (e.g. cTNM and the other 
pTNM) since every cancer episode can only be registered once in the 
Cancer Registry. Another explanation for the low accuracy could be 
uncertainty of the timing of the reporting of TNM components, e.g. before or 
after neo-adjuvant therapy (which may have reduced the tumour size) or 
surgery (which allows histopathological examination and therefore more 
accurate staging). Unfortunately, the time point is not required to be reported 
when the information is submitted to the Cancer Registry. Although pTNM is 
the recommended TNM to report whenever available (which it is in all 
patients included in the present study), TNM was unclear or based on cTNM 
in the majority of patients, although it was stated that the diagnosis for all 
included patients was based on “biopsy or operation with histopathological 
investigation”. Therefore, it may also be that the source of TNM is reported 
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incorrectly as cTNM in some cases since the pathology data should have 
been available at that time. Unfortunately, distinguishing between biopsy and 
full histopathological investigation of the resected oesophagus was not 
possible because these data were not provided.  
 
The main implications of these results are that pTNM is underreported, 
although it is requested by the Cancer Registry. However, the overall tumour 
stage is reliable for patients operated for oesophageal cancer, even when 
based on the cTNM or when it is unclear how the TNM is determined. In 
many cases, separate T, N and M components appeared to be unreliable. 
The generalisability of these finding to other types of cancer are uncertain, 
but it is reasonable to assume that the problems encountered in the present 
study population would also exist for other tumours. However, the results 
might not be generalisable to non-operated patients, since the pTNM is not 
available. 
 
To conclude, this nationwide Swedish validation study showed that the 
overall pTNM stage is incompletely reported, although this is compensated 
by a better reporting of cTNM staging and staging based on unspecified 
assessment. The T, N and M components are suboptimally reported. It is 
important to improve the assessment of tumour stage in the Swedish Cancer 
Registry, including making it clear by whom and when the reporting is 
supposed to be done, and highlighting the need to report both the cTNM and 
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Table 1: Descriptive characteristics of the cohort of patients operated 
















Total 397 (100.0) 104 (26.2) 183 (46.1) 110 (27.7) 
Sex 
    Men 312 (100) 86 (27.6) 136 (43.6) 90 (28.9) 
Women 85 (100) 18 (21.2) 47 (55.3) 20 (23.5) 
Age (years) 
    <61 138 (100) 39 (28.3) 59 (42.8) 40 (29.0) 
61-67 128 (100) 34 (26.6) 62 (48.4) 32 (25.0) 
>67 131 (100) 31 (23.7) 62 (47.3) 38 (29.0) 
Year of resection 
    2006 78 (100) 5 (6.4) 7 (9.0) 66 (84.6) 
2007 75 (100) 21 (28.0) 27 (36.0) 27 (36.0) 
2008 57 (100) 19 (33.3) 34 (59.7) 4 (7.0) 
2009 100 (100) 33 (33.0) 63 (63.0) 4 (4.0) 
2010 87 (100) 26 (29.9) 52 (59.8) 9 (10.3) 
Histological tumour 
type 
    Squamous cell carcinoma 163 (100) 40 (24.5) 74 (45.4) 49 (30.1) 
Adenocarcinoma 212 (100) 52 (24.5) 105 (49.5) 55 (25.9) 
Other 22 (100) 12 (54.6) 4 (18.2) 6 (27.3) 
Hospital type 
    University 240 (100) 50 (20.8) 119 (49.6) 71 (29.6) 
Non-university 157 (100) 54 (34.4) 64 (40.8) 39 (24.8) 
Hospital volume  
(average per year) 
    1-8 oesophagectomies 102 (100) 33 (32.4) 42 (41.2) 27 (26.5) 
9-16 oesophagectomies 157 (100) 41 (26.1) 75 (47.8) 41 (26.1) 
16-21 oesophagectomies 138 (100) 30 (21.7) 66 (47.8) 42 (30.4) 
Legend: pTNM, pathology based TNM staging; cTNM, clinically based TNM 




Table 2: Completeness and concordance of the tumour stage and TNM 
components between the Swedish Cancer Registry and a comparison 
clinical cohort of patients receiving resection for oesophageal cancer 









% Kappa SE p 
T 101 (97.1) 82.7 28.6 0.76 0.06 <0.001 
N 103 (99.0) 95.2 49.9 0.90 0.10 <0.001 
M 89 (85.6) 81.7 77.1 0.20 0.05 <0.001 
Stage 102 (98.1) 98.1 33.9 0.97 0.06 <0.001 
  








% Kappa SE p 
T 169 (92.3) 31.7 26.3 0.07 0.04 0.029 
N 175 (95.6) 59.6 48.4 0.21 0.07 0.001 
M 174 (95.1) 88.5 86.0 0.18 0.05 <0.001 
Stage 180 (98.4) 98.4 29.3 0.98 0.05 <0.001 
  









% Kappa SE p 
T 85 (77.3) 53.6 22.4 0.40 0.05 <0.001 
N 83 (75.5) 65.5 37.7 0.45 0.07 <0.001 
M 75 (68.2) 65.5 64.3 0.03 0.03 0.110 
Stage 108 (98.2) 98.2 29.8 0.97 0.06 <0.001 
  
 










%  Kappa  SE p 
T 355 (89.4) 51.1 26.1 0.34 0.03 <0.001 
N 361 (90.9) 70.5 45.8 0.46 0.04 <0.001 
M 338 (85.1) 80.4 77.7 0.12 0.02 <0.001 
Stage 390 (98.2) 98.2 29.8 0.97 0.03 <0.001 
Legend: pTNM, pathology based TNM staging; cTNM, clinically based TNM 
staging; SE, standard error. * T was categorised in 4 groups (T0-1, T2, T3 or 
T4), N in 2 groups (N0 or N1), M in 2 groups (M0 or M1) and tumour stage in 
4 groups (0-1, II, III, or IV).   
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Figure 1: The TNM classification for oesophageal cancer, adapted from 
the Union International Contre le Cancer (UICC) 6th edition.  
 
Stage 0-I T0NanyM0  or T1N0M0 
Stage II T2,3N0M0 or T1,2N1M0 
Stage III T3N1M0 or T4NanyM0 
Stage IV TanyNanyM1  
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Figure 2: Flowchart describing the selection of the validation cohort of 
patients, operated for oesophageal cancer in Sweden. 
 
Legend: pTNM, pathology based TNM staging; cTNM, clinically based TNM 
staging. 
